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routine clinical practice. As its determination is be-
coming more routinely done, SSc autoantibodies may
“work” as predictors of a specific organ involvement, of
prognosis and survival, in the several subtypes of the
disease, historically just divided in limited and diffuse,
based on the extend of skin involvement.
Thus, integrating the knowledge of these various as-
pects of the disease, rheumatologists can, in a more
careful and targeted way, monitor and recognize po-
tential internal involvement organ, as well as, potential
complications and introduce treatment earlier. For this
to be accomplished, it is important to perform regular
patients follow-up and screening for pulmonary hy-
pertension. In what concerns this complication, regu-
lar screening clearly improved patient’ survival3. 
At present time, there is still no drug that treats
broadly all SSc manifestations, targeting and truly 
acting on the mechanism of fibrosis. Targeting poten-
tial fibrosis and vascular mediators is, or has been un-
derway, but not always successful. The paper from Cu-
tolo et al.4 in this edition, apart from the physiopatho-
logic review, summarizes potential therapeutic targets
in SSc.
At this time point, and despite attempts targeting in-
flammatory, vascular and pro-fibrotic molecules, just
few of them are available for clinical practice. Patients
are treated based on their clinical manifestations and re-
lated severity and, besides pulmonary arterial hyper-
tension and digital ulcers, usually through immuno-
suppressive agents and symptomatic treatment.
Pulmonary hypertension, if diagnosed as group I of
PH classification5 (Pulmonary arterial hypertension),
has an effective therapy, but most SSc patients show
other concurrent PH causes as interstitial lung disease,
thrombo-embolic disease or left heart dysfunction,
making it more challenging to treat. 
As so, methotrexate remains the first therapeutic
choice. For interstitial lung disease (ILD) cyclophos-
phamide is used in clinical practice but has only shown
modest beneficial effect on lung function and dyspnea6.
More recently, encouraging results have been docu-
mented with mycophenolate and rituximab, and these
The 4th World Systemic Sclerosis Congress 2016 took
place in Lisbon, and the more than 1000 registered
health professionals and patients, gathered to learn
more about the disease and its current management. 
Systemic Sclerosis (SSc) is characterized by vascular
inflammation, vascular hyper-reactivity and excess tis-
sue collagen deposition. These pathologic changes lead
to macro and microvascular injury and to fibrosis of
the skin and internal organs resulting in organ damage.
Unfortunately, the exact mechanism and triggers for
endothelial dysfunction and perpetuation of patholo -
gic changes are only partially understood and still need-
ing further research. 
Since the last few decades and nowadays, the mani -
festations that most contribute to the increased SSc
mortality are lung disease and pulmonary hyperten-
sion, accounting for nearly 30% of scleroderma-rela -
ted deaths1.
Besides the higher mortality rate, SSc also has a high
impact on patients’ quality of life becoming a real and
heavy burden. Gastrointestinal involvement, Raynaud’s
phenomenon and particularly, digital ulcers, increase
disability and reduce quality of life. Furthermore, dys-
pnoea arising from interstitial lung disease, pulmonary
fibrosis and pulmonary hypertension (PH) also inter-
fere and disable patients to accomplish their routine
daily activities.
Therefore, an early diagnosis is mandatory. The new
SSc classification criteria (ACR/EULAR 2013)2 reflects
the need to create an earlier treatment window of op-
portunity, based on a better understanding of the patho-
physiology of the disease, recognizing the importance
of capillaroscopy in early diagnosis, and the role of the
specific SSc autoantibody profile in clinical manifesta-
tions and disease prognosis.
Specific SSc autoantibodies are very rare in other
disea ses, are generally present on disease onset, and do
not change over the course of the disease. Autoanti-
body profile in SSc has been extensively studied but,
until recently, was not widely performed/available in
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agents may be considered as options in treating inter-
stitial lung disease7. The EULAR guidelines for Sistemic
Sclerosis are being updated and will be published this
year. 
But hope arises as clinical trials in SSc are in creasing. 
Pirfenidone is an oral pyridine compound, and
nintedanib is a tyrosine kinase inhibitor including
PDGFRa and β (platelet-derived growth factor recep-
tor), FGFR 1-3 (fibroblast growth factor receptor) and
VEGFR 1-3 (vascular endothelial growth factor recep-
tor). Both pirfenidone and nintedanib are effective and
approved for the treatment of idiopathic pulmonary
fibrosis. Nintedanib has already an ongoing trial in in-
terstitial lung disease, in systemic sclerosis patients.
Tocilizumab, a humanized interleukin-6 (IL-6) re-
ceptor antagonist initially approved for rheumatoid
arthritis demonstrated encouraging results in a phase
II/III randomized controled trial in SSc patients, by
ameliorating modified Rodnan skin score8. These re-
sults granted tocilizumab a breakthrough therapy de -
signation for SSc by FDA ( U.S. Food and Drug Admi -
nistration), in 2015. Another phase III trial in SSc pa-
tients is also ongoing/recruiting. Other molecules are
being investigated with promising preliminary results.
The pro-fibrotic transforming growth factor beta (TGF)
pathway can be inhibited by fresolimumab and rio-
ciguat. Fresolimumab, a monoclonal antibody to TGF
beta, improved modified Rodnan skin score in SSc pa-
tients (Rice LM et al. Fresolimumab treatment de-
creases biomarkers and improves clinical symptoms
in systemic sclerosis patients. J Clin Invest. 2015;125
(7):2795–2807). Riociguat, a guanilciclase stimulator
blocks TGF beta signalling (Dees C et al. Stimulators
of soluble guanylate cyclase (sGC) inhibit experimen-
tal skin fibrosis of different aetiologies. Ann Rheum
Dis. 2015;74(8):1621-5), and has a phase II study un-
derway.  Terguride, a serotonin antagonist (5HTR2B),
is also expected to have clinical trials in patients with
systemic sclerosis, regarding cutaneous and vascular
endpoints.
Learning more about SSc manifestations, regular
screenings, general care measures and patient educa-
tion/empowerment is halfway in preventing compli-
cations and improving care. 
Regarding therapy, SSc is finally getting a “breath of
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